Current Report
Filed: 2026-03-27
Key Insights
- ABVC BioPharma held its 2026 annual meeting, where shareholders re-elected all 11 directors and approved an increase in the company's equity incentive plan to 15% of outstanding shares.
- The company appointed Simon & Edward, LLP as its independent registered public accounting firm for fiscal year 2026.
- The increase in the equity incentive plan size suggests the company may be focused on employee retention and incentives to drive future growth.